Community Research and Development Information Service - CORDIS

H2020

MEDMICO Report Summary

Project ID: 666676

Periodic Reporting for period 1 - MEDMICO (Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform)

Reporting period: 2015-07-01 to 2016-06-30

Summary of the context and overall objectives of the project

Diabetes affects 8.5% (2013) of the adult European population rising to 10.3% (2035) and is associated with co-morbid conditions such as cardiovascular and renal abnormalities. These lead to diabetic complications, ischemic heart disease, heart failure and kidney failure. Management of this growing epidemic requires a shift in care management and delivery, away from central lab testing. The majority of current diagnostic monitoring for diabetes, heart disease, kidney disease and their associated complications still involves large needles and vials of blood being transported to central laboratories for testing and long waits for results.

To address the need for instant testing of any chronic disease from a finger-prick of blood on a single blood testing device, Radisens Diagnostics proposed the MEDMICO project, to develop the worlds first PoCT platform integrating the primary blood testing families of immunoassays, turbidimetry, clinical chemistry and cell counting. The European Commission have funded this project (proposal number: SEP-210218471) under the H2020 call H2020-SMEINST-2-2014, Topic: PHC-12-2014.

Under MEDMICO, HbA1c, Lipids and Creatinine tests will be integrated on to a single diabetes comorbid platform to diagnose and monitor patients, within primary care, outpatient clinics and pharmacies. This will improve patient outcomes and healthcare efficiencies, positioning Europe at the forefront of healthcare innovation and deliver an efficient platform to combat this epidemic.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Several deliverables have been submitted during the period to the European Commission for their confidential review by industry experts. These summarise the first phase integration of the target chronic disease panels onto the Gemini platform, with early method comparison data, the platform's miniaturisation and manufacturing process development progress.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

MEDMICO will integrate panels for diabetes, cardiovascular disease and kidney disease onto its multi-mode Gemini point of care platform, delivering central laboratory performance, room temperature storage and removing the need for over-night fasting by patients. MEDMICO plans to tackle the lack of access to clinical diagnostics to society by integrating multiple clinical diagnostic needs within one multi-mode device, offering ease of use and simplified logistics,. This addresses the lack of access by empowering decentralised healthcare settings to embrace this novel platform. MEDMICO will aim to go further by targeting the pharmacy sector, thereby opening the possibility of weekend healthcare access to society. Providing greater access to healthcare for chronic disease sufferers, with a single healthcare visit and immediate diagnostic results will positively impact society, thereby improving patient outcomes, lowering chronic risk factors and will reduce the huge burden on healthcare system resources.

Related information

Record Number: 190411 / Last updated on: 2016-11-15
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top